Tricida (TCDA) with 2000 January $10/$20 call spreads opening, small cap Biotech started Buy at Goldman in April with $25 target optimistic on the outlook for the company’s development of veverimer in metabolic acidosis with chronic kidney disease considering the safety and efficacy in three previous placebo-controlled clinical studies ahead of the results of a phase 3 study expected in Q4. These call spreads are targeting positive results though the name has 16% of the float short, the $565M Co. trading 4.55X Cash.